title: [Treatment of mouse liver metastasis by intraportal injection of Adv-p53].
abstract: OBJECTIVE
  To investigate the anti-tumor effect of intraportal administration of Adv-p53 in the treatment of the liver metastasis in mice.
  
  
  METHODS
  2 x 10(5) of MCA-205 cells were injected into the mouse portal vein to establish a murine liver metastasis model. The spleen was transpositioned subcutaneously to enable the administration of Adv-p53 continually into the portal system. Different doses of Adv-p53 were injected intraportally, while HBSS and Adv-CMV were injected intraportaly in the control group. Tumors in the liver were examined on day 21 after Adv-p53 administration.
  
  
  RESULTS
  The liver weight in the Adv-p53 treated mice on day 0 group (1.20 +/- 0.34 g) was significantly less than that in the Adv-CMV group (2.59 +/- 0.48 g, P < 0.05). The number of metastatic nodules in the Adv-p53 treated mice on day 0 group (9.0 +/- 9.9) was significantly less than that in the Adv-CMV group (57.1 +/- 11.3, P < 0.05), indicating that intraportal administration of Adv-p53 inhibited the formation of liver metastasis. This anti-tumor effect was in a dose-dependent manner. After the liver metastasis was formed, Adv-p53 was administered intraportally. The liver weight in the Adv-p53 treated mice on day 5 group (1.22 +/- 0.09 g) was significantly less than that in the Adv-CMV group (3.98 +/- 1.01 g , P < 0.05). The number of metastatic nodules in the Adv-p53 treaed mice on day 5 group (5.5 +/- 3.5) was significantly less than that in the Adv-CMV group (113.2 +/- 5.8, P < 0.05). Repeatedly intraportal administration of Adv-p53 could enhance this anti-tumor effect.
  
  
  CONCLUSIONS
  Local administration of Adv-p53 into the portal system would be a useful strategy for the liver metastasis treatment.
authors.affiliation: Department of General Surgery, Beijing Hospital, Beijing 100730, China. suwei1@medmail.com.cn
authors.forename: Wei
authors.initials: W
authors.lastname: Su
authors.forename: Jin-Hua
authors.initials: JH
authors.lastname: Zhang
authors.forename: Han-Wei
authors.initials: HW
authors.lastname: Liu
authors.forename: Gang
authors.initials: G
authors.lastname: Xiao
authors.forename: Xin-Ping
authors.initials: XP
authors.lastname: Zhou
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Sun
authors.forename: Cheng-Jian
authors.initials: CJ
authors.lastname: Liao
authors.forename: Mei-Xiong
authors.initials: MX
authors.lastname: Huang
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D005260:Female; D005354:Fibrosarcoma / Q000473:pathology*; D015316:Genetic Therapy; D008114:Liver Neoplasms, Experimental / Q000556:secondary / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D016159:Tumor Suppressor Protein p53 / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53